WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Acromax Laboratorio Químico Farmacéutico S.A.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Pharmacy Market
Eagle Pharmaceuticals, Inc. | March 29, 2022
Eagle Pharmaceuticals, Inc. reported that it had achieved an agreement with Acacia Pharma Group plc on the parameters of a plan of arrangement under Part 26 of the United Kingdom's Companies Act 2006. Acacia Pharma's current issued and to be issued, share capital is valued at approximately €94,700,000, or the equivalent of €0.90 per share, under the terms of the proposed transaction. Each Acacia Pharma shareholder would get €0.68 in cash and 0.0049 shares of...
Amarin spurns | August 05, 2020
Amarin's wild 2020 ride continues. Tuesday, the company said COVID-19 took a bite out of second quarter earnings, and it unveiled plans to launch its fish-oil derivative drug Vascepa in Europe without help from a bigger marketing partner. And that's on top of prepping for federal court this fall, where it will try to salvage Vascepa's key patents. Amarin positioned its European plans as a positive: It did receive multiple proposals from potential partners. But the significant sales o...
Business Insights
Alnylam Pharmaceuticals, Inc. | April 05, 2022
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration has extended the review timeline of the New Drug Application for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labeling facility. Alnylam recently learned that the original third-party secondary packaging and l...
BioTechniques | April 08, 2020
Providing the latest updates in the understanding of coronavirus, drug development and clinical trials for a vaccine for COVID-19. A study seeking to determine which of the lung and bronchi cells are targets for SARS-CoV-2 has been recently published in The EMBO Journal, suggesting the target is progenitor cells that usually develop into respiratory tract cells lined with cilia. This follows previous research that had demonstrated that the virus spike protein attaches to the ACE2 receptor on cel...
Business Insights, PHARMA TECH
Video
Research, Business Insights
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE